Quantcast

Latest Atopy Stories

2014-07-10 10:20:50

University of Rochester Medical Center URMC-led study offers hope for atopic dermatitis sufferers An investigational medication shows promise in treating the most common skin disorder, often referred to as eczema or atopic dermatitis, according to a study published July 9 in the New England Journal of Medicine. The findings could eventually bring significant relief for many who suffer intense itching and other troubling features of atopic dermatitis, according to the study's lead...

2014-07-09 16:28:51

Results from Earlier Clinical Trials Published Today in the New England Journal of Medicine TARRYTOWN, N.Y. and PARIS, July 9, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema. All doses of dupilumab met the primary endpoint...

2014-07-09 08:28:37

EpiCeram(R) Controlled Release Skin Barrier Emulsion now offers dosing flexibility with 2 sizes SOUTH PLAINFIELD, N.J., July 9, 2014 /PRNewswire/ -- PuraCap(TM) Pharmaceutical today announced the newest addition to the EpiCeram(R) product line, the EpiCeram(R) 225g Airless Pump. The unique airless pump gives patients more EpiCeram(R) to treat any size area of atopic dermatitis. The special dispensing system allows for more control, delivering EpiCeram(R) consistently and precisely...

2014-07-08 23:15:50

Dignity Sciences Limited finds that a DGLA topical cream (DS107E) has an overall dose response improvement for Atopic Dermatitis in a Phase II clinical trial. Dublin, Ireland (PRWEB) July 08, 2014 Dignity Sciences Limited, a privately held biopharmaceutical company, today announced positive Phase II results for DS107E (DGLA cream), as a topical treatment for atopic dermatitis. This study was a randomized, placebo-controlled, double-blind, multi-centre Phase II study to investigate the...

2014-06-17 12:30:09

Partnership Represents LETI's Inaugural Launch in North America CHATHAM, N.J., June 17, 2014 /PRNewswire/ -- DermWORX Professional Skincare and LETI Laboratories announce plans to launch a series of top European dermatological products in the United States. This includes LETI's leading dermatology line for atopic skin, AT4, which DermWORX will market to U.S. healthcare professionals and their patients beginning in Q3, 2014. LETI Laboratories, a strategic founding partner for...

2014-05-28 08:31:16

MONROVIA, Calif., May 28, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the first subject has been dosed in a Phase 1a clinical trial of XmAb®7195. XmAb7195 is a monoclonal antibody engineered to suppress IgE via three distinct mechanisms of action as a potential treatment for asthma and...

2014-05-07 08:37:47

Eczema caused by defects in the skin could reduce the risk of developing skin cancer, according to new research by King's College London. The immune response triggered by eczema could help prevent tumor formation by shedding potentially cancerous cells from the skin. There is ongoing debate surrounding allergic diseases and their impact on the likelihood of developing cancer, with some studies suggesting that eczema is associated with a reduced risk of skin cancer. However, it is difficult...

2014-04-16 16:30:36

LONDON, April 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_atopic_dermatitis_global_drug_forecast_market_analysis_2022.htmlPharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2022 SummaryAlthough the past decade has seen the atopic dermatitis market remain relatively unchanged...

2014-04-16 16:26:34

LONDON, April 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:PharmaPoint: Atopic Dermatitis - US Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_atopic_dermatitis_us_drug_forecast_market_analysis_2022.htmlPharmaPoint: Atopic Dermatitis - US Drug Forecast and Market Analysis to 2022SummaryAlthough the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated,...

2014-04-08 23:32:46

A new site devoted to eliminating eczema (GetRidOfEczema.org) launches with 15 powerful tips you can implement right now to get rid of eczema without using drugs. New York, NY (PRWEB) April 08, 2014 Eczema, also known as atopic dermatitis, is a tremendously common skin problem. In fact, as much as 10% of the entire human population is estimated to have experienced eczema symptoms at some point in their lives. Most of the time, these symptoms subside after childhood. But for millions of...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related